PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Nadeem Riaz, MD, MSc - Deep Insight Into Immuno-Oncology: A Visual Exploration of Current and Emerging Pathways, Targets, and Biomarkers to Maximize the Potential of Cancer Immunotherapies


Go online to PeerView.com/KNT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an immuno-oncology expert describes the basic biology of how the immune system responds to tumor activity, reviews the pathophysiology of the tumor microenvironment, provides up-to-date data supporting the use of cancer immunotherapies, including immune checkpoint inhibitors, and discusses investigational immuno-oncology pathways, putative targets for novel therapies, and current and emerging prognostic biomarkers to inform clinical treatment decisions. Upon completion of this activity, participants will be able to: Describe the foundational aspects of the immune system’s response to tumor activity through innate and adaptive immunity mechanisms, Review the pathophysiology of the tumor microenvironment and its relationship to tumor evasion and resistance, Characterize the mechanisms of action of the immune checkpoint inhibitors (ie, CTLA-4 and PD-1/PD-L1 inhibitors) and how they differ in their activity and adverse effects from conventional anticancer therapies, Summarize the current FDA-approved indications and investigational approaches with the immune checkpoint inhibitors across different tumors, Discuss investigational immuno-oncology pathways and potential new therapies that may be able to expand on the current therapies or overcome immune evasion and resistance, Assess current and emerging immuno-oncology biomarkers and their potential roles/uses, Integrate the latest immunotherapies and biomarker approaches into cancer care in the context of clinical practice or trials.


share







 2020-06-05  1h3m